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ABSTRACT 20 
Reliable, simple and rapid methods for laboratory detection of carbapenemases are important for 21 
an appropriate antibiotic administration.  A nitrocefin disc containing ertapenem for rapid 22 
screening of carbapenemase production among Enterobacteriaceae is developed in the present 23 
study.  A total of 87 molecularly-confirmed Enterobacteriaceae including 31 carbapenemase 24 
producers and 56 non-carbapenemase producers, were tested with nitrocefin discs supplemented 25 
with and without ertapenem (20 µg/ disc).  Nitrocefin discs with ertapenem successfully 26 
discriminated all 31 carbapenemase and all non-carbapenemase producers within 30 minutes. 27 
The sensitivity and specificity of the method were 100%. The minimum inhibitory 28 
concentrations (MICs) of ertapenem against all carbapenemase-producing isolates ranged from 1 29 
to ≥  256 g/mL. This simple test could help to minimize the treatment failure and control the 30 
dissemination of infections caused by carbapenemase-associated resistant bacteria.  It is a 31 
promising approach that could be performed routinely in any laboratory.   32 
 33 
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1. Introduction 41 
Since carbapenems have been extensively used for the treatment of infections caused by AmpC 42 
and extended-spectrum β-lactamase (ESBL)-producing isolates, an emergence of carbapenem-43 
resistant Enterobacteriaceae (CRE) has been identified (Jacoby, 2009; Perez et al., 2007). 44 
Prevalence of CRE has been increasing dramatically, becoming one of the most serious clinical 45 
issues with increased morbidity and mortality worldwide (Logan and Weinstein, 2017). The 46 
mechanism of resistance to carbapenems, the last line β-lactam antibiotics for the treatment of 47 
Gram-negative bacterial infections, is predominantly mediated by enzymes called 48 
“carbapenemases” (Bush and Fisher, 2011). Resistance also involves a variety of other 49 
mechanisms, including overproduction of AmpC β-lactamase or ESBL combined with decreased 50 
porin channel for carbapenem entry, and increased efflux pump activity (Thomson, 2010). 51 
Colistin, fosfomycin and tigecycline are among the most frequently used antibiotics for the 52 
treatment of carbapenem resistance (Lee and Doi, 2014). 53 
The carbapenemase gene (blaNmcA) was first proven in the chromosome of Enterobacter cloacae 54 
in France in 1993 (Naas and Nordmann, 1994).  In 1995, a plasmid-encoded bla IMP -1 was 55 
described in Japan in Serratia spp.  This metallo-β-lactamase ( MBL)  was able to hydrolyze 56 
carbapenem antibiotics (Ito et al., 1995). A few years later, carbapenem-hydrolyzing blaKPC-1 and 57 
blaKPC-2 gene were identified in a plasmid of Klebsiella pneumoniae (Smith Moland et al., 2003; 58 
Yigit et al., 2001). Furthermore, OXA-48 carbapenemase was also first discovered and identified 59 
in an isolate of carbapenem-resistant K.  pneumoniae in Istanbul, Turkey (Poirel et al., 2004). 60 
Even though numerous clinically significant carbapenemase-encoded genes have been identified 61 
recently, they can be molecularly grouped into Ambler class A (KPC and GES), class B (MBL: 62 
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NDM, VIM, and IMP) , and class D with carbapenemase activity ( OXA-48-like)  (Nordmann, 63 
2014).  64 
Currently, treatment options available for the treatment of infections caused by CRE are limited. 65 
Development of diagnostic tools to detect the presence of carbapenemase in Enterobacteriaceae 66 
is necessary to guide clinicians for appropriate antimicrobial therapy, as well as to minimize 67 
treatment failure (Teethaisong et al., 2016). A number of innovative methods such as genotypic 68 
(e.g. multiplex PCR and real-time PCR), phenotypic (e.g. disc-inhibitor synergy test), and 69 
biochemical tests (e.g. Carba NP test), have been developed for the detection of carbapenemase-70 
producing isolates (Osei Sekyere et al., 2015; Tamma et al., 2017). However, they are relatively 71 
time-consuming, or expensive and difficult to perform.   72 
Nitrocefin, a chromogenic cephalosporin, is a substrate for β-lactamase enzymes. The reaction 73 
can visually be observed by a change its original yellow color to red. Nitrocefin assay is one of 74 
the most common methods to detect the presence of β-lactamases in both Gram-negative and 75 
Gram-positive bacteria ((Kaase et al., 2008)). Carbapenem antibiotics prevent extended spectrum 76 
β-lactamase (ESBL) and AmpC β-lactamase-producing bacteria from hydrolyzing nitrocefin 77 
(Goessens et. al., 2013 ). The present study, therefore, developed a novel chromogenic method 78 
using a nitrocefin disc impregnated with ertapenem for rapid screening of carbapenemase 79 
production in Enterobacteriaceae isolates. 80 
 81 
2. Materials and methods 82 
2.1 Bacterial isolates 83 
 A total of 87 Enterobacteriaceae isolates with confirmed molecular types of β-lactamase 84 
enzymes were used in the present study as summarized in Table 1.  The bacterial strains used 85 
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have been described in our previous study (Teethaisong et al., 2016; Teethaisong et al., 2017), 86 
with an addition of KPC-producing K. pneumoniae 4018. Thirty-one carbapenemase-producing 87 
isolates (11 MBLs, 9 KPCs and 11 OXA-48), fifty-six non-carbapenemase-producing strains and 88 
a β-lactamase-negative E. coli ATCC 25922 were used to investigate nitrocefin discs 89 
supplemented with and without ertapenem for the rapid screening of carbapenemase production 90 
in Enterobacteriaceae.     91 
2.2 Minimum inhibitory concentration (MIC) determination 92 
 The MICs of ertapenem were assessed by a standard broth microdilution method according to 93 
the Clinical and Laboratory Standards Institute (CLSI) guideline (Clinical Laboratory Standards 94 
Institute, 2012). The organisms (18-h culture) were collected by centrifugation and washed twice 95 
with sterile saline before adjusting to obtain a 0.5 Mcfarland standard. MIC determination was 96 
performed by adding 20 µL of adjusted and diluted organisms (5 x 106 CFU/mL) to the wells 97 
containing 20 µL of a doubling dilution series of ertapenem (final concentration ranging from 0. 98 
25 - 256 µg/mL) and 160 μL of Mueller-Hinton culture medium. The total volume in each well 99 
was 200 μL. The 96-well microtiter plate was then incubated for 20 h at 37˚C. Wells without 100 
bacteria and ertapenem were used as controls. The experiment was carried out in triplicate. The 101 
lowest concentration showing no visible growth was noted as MIC value. The susceptibility 102 
profile of ertapenem was interpreted in accordance with CLSI susceptibility breakpoint: 103 
Susceptible ≤ 0.5, intermediate = 1 and resistant > 1 µg/mL (Clinical Laboratory Standards 104 
Institute, 2014).  105 
2.3 Disc preparation and experimental procedure 106 
 For the preparation of discs, nitrocefin discs (MAST Diagnostic group, UK) were impregnated 107 
with and without 10 µL of ertapenem (Sigma-Aldrich) at a concentration of 2 mg/mL to obtain 108 
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ertapenem final amount of 20 µg/disc. Following discs had been air-dried in a cabinet, they were 109 
stored at -20ºC. The discs were allowed to equiplibrate to room temperature before use.  To 110 
screen for the presence of carbapenemases in Enterobacteriaceae, two nitrocefin discs (one with 111 
and one without ertapenem) were directly placed on 18-h culture colonies grown on LB agar. 112 
Following incubation at 37ºC for 30 min, the result was visually observed and interpreted. The 113 
development of a red color in the area of both discs with and without ertapenem was denoted as a 114 
positive result for carbapenemase, while no color changes in both discs or color change only in 115 
nitrocefin without ertapenem disc indicated no carbapenemase production. 116 
 117 
3. Results  118 
The present study demonstrates the use of a nitrocefin disc with ertapenem for rapid screening of 119 
carbapenemase-producing isolates. The performance of the method was determined by a sum of 120 
87 known molecular types of β-lactamase-producing Enterobacteriaceae. The distribution of 121 
MICs of ertapenem among 31 carbapenemase producers and 56 non-carbapenemase producers 122 
are presented in Fig. 1. In KPC producers, the MICs of ertapenem ranged from 16 to ≥ 256 123 
µg/mL, while in MBL producers, MICs ranged from 8 to ≥ 256 µg/mL. These MIC values 124 
indicated that all MBL and KPC producers were resistant to ertapenem. MICs of ertapenem 125 
against OXA-48 producers ranged from 1 to 256 µg/mL. These values trended lower than those 126 
MICs of KPC and MBL producers. The susceptibility profile of one OXA-48-E. coli was 127 
intermediate. Furthermore, the majority of non-carbapenemase producers were susceptible to 128 
ertapenem. Five AmpC-producing isolates were found in the intermediate range. The MIC of 129 
ertapenem against a reference E. coli ATCC 25922 was ≤ 0.25 µg/mL which was classified as 130 
susceptible.  131 
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Fig. 1. The distribution of MIC values of ertapenem against distinct types of β-lactamase-147 
producing Enterobacteriaceae. Red dotted line indicates resistant breakpoint according to CLSI 148 
guidelines. 149 
 150 
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The use of nitrocefin discs with and without ertapenem successfully differentiated 151 
carbapenemase producers from other types of β-lactamase producers within 30 min as illustrated 152 
in Fig. 2. The study demonstrated that the color of both discs with and without ertapenem 153 
developed from yellow to red in all 31 carbapenemase producers. In non-carbapenemase 154 
producers, the color change from yellow to red was observed only in the area of an ertapenem-155 
free disc. No color change in both discs was seen in a control strain E. coli 25922. The sensitivity 156 
and specificity of the method were 100%. Interestingly, the diagnostic method developed in this 157 
study can detect the presence of OXA-48 carbapenemase enzyme in an ertapenem-intermediate 158 
E. coli. It can also discriminate the absence of carbapenemase in ertapenem-intermediate isolates 159 
harboring hyperexpressed AmpC β-lactamase. Furthermore, some of ESBL and AmpC-160 
producing strains used in the current study were also previously found to be hyperprodution of 161 
ESBL and AmpC β-lactamases (Teethaisong et al., 2016 and 2017). 162 
4. Discussion  163 
The first carbapenemase detection assay was based on antibiotic susceptibility profile from disc 164 
diffusion method and MIC determination. The interpretation relies on susceptibility breakpoint. 165 
Ertapenem is thought to be a good indicator for the detection of carbapenemase-associated 166 
resistance in Enterobacteriaceae as it usually shows higher MIC values compared with those of 167 
imipenem and meropenem (Nordmann et al., 2012; Vading et al., 2011). Due to reduced 168 
sensitivity and specificity, detection of carbapenemase producers based on susceptibility profile 169 
is not frequently conducted (Nordmann and Poirel, 2013). Since then, various methods have been 170 
developed and described. Carba NP, a biochemical test, is one of the most popular methods that 171 
has been extensively used by many laboratories to detect the presence of carbapenemases in 172 
Gram-negative bacteria. This test can provide the result in less than 2 h (Dortet et al., 2012).  173 
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However, the preparation for manual Carba NP is relatively difficult. In addition to Carba NP, a 174 
β-CARBATM test showed good performance in dectection of carbapenemases-producing isolates 175 
with sensivity 100% of KPC, 100% of IMP, 96.4% of VIM, 85.3% of NDM, 80.5% of OXA-48-176 
like carbapenemases. This test exhibited poor specificity for  non-KPC Ambler class A and 177 
OXA-48-like carbapenemases (Bernabeu et al., 2017). A method developed in the present study 178 
is a simple promsing method that successfully screen carbapenemase production in 179 
Enterobacteriaceae within 30 min. It could be an alternative method for identifying 180 
carbapenemase-mediated resistance in Enterobacteriaceae and other Gram-negative bacilli.       181 
 182 
 183 
 184 
 185 
 186 
 187 
 188 
 189 
 190 
 191 
 192 
 193 
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Fig. 2. Representative results from nitrocefin disc with and without ertapenem at 30 min of 194 
incubation at 37oC. A = nitrocefin disc alone; B = nitrocefin disc supplemented with ertapenem 195 
(20 µg/disc). (I), 1) = KPC-2-producing K. pneumoniae  4016; 2) = NDM-1-producing E. coli  196 
4011; 3) = SHV-27 + TEM-53-producing K. pneumoniae  1012; 4) = a susceptible reference 197 
strain E. coli ATCC 25922. (II), 5) = IMP-1-producing Klebsiella ozaenae  403; 6) = OXA-48-198 
producing K. pneumoniae  4019; 7) = ACT-32-producing E. cloacae  2009; 8) = TEM-199 
214+SHV-12+ACT-32-E. aerogenes  3009. 200 
 201 
The nitrocefin disc supplemented with ertapenem perfectly detected carbapenemase producers 202 
with low ertapenem MIC values, particularly OXA-48-like-producing isolates. However, this 203 
method needs to be further validated with carbapenem-susceptible isolates as well as with other 204 
carbapenemase variants. It also requires larger sample sizes of carbapenemase-producing isolates 205 
to confirm the robustness of this assay. The performance of the assay should be investigated with 206 
other carbapenemase-producing Gram-negative bacteria such as Pseudomonas spp. and 207 
Acinetobacter spp. Subjectivity in interpretation of the results is not only the common issue of 208 
this method, but it is also a problem of all other chromogenic methods (Tijet et al., 2013). 209 
In conclusion, the nitrocefin with ertapenem disc is very simple to perform and provides rapid 210 
results to identify carbapenemase producers, with high sensitivity and specificity. This assay can 211 
be carried out routinely in any microbiological laboratory. It could facilitate successful treatment 212 
of carbapenemase-mediated resistance and indicate the isolates to be further evaluated by PCR or 213 
sequencing for molecular epidemiological surveillance. This method is also potentially important 214 
for follow-up investigations.  215 
 216 
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Fig. 1. The distribution of MIC values of ertapenem against distinct types of β-lactamase-312 
producing Enterobacteriaceae. Red dotted line indicates resistant breakpoint according to CLSI 313 
guidelines. 314 
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Fig. 2. Representative results from nitrocefin disc with and without ertapenem at 30 min of 327 
incubation at 37oC. A = nitrocefin disc alone; B = nitrocefin disc supplemented with ertapenem 328 
(20 µg/disc). (I), 1) = KPC-2-producing K. pneumoniae  4016; 2) = NDM-1-producing E. coli  329 
4011; 3) = SHV-27 + TEM-53-producing K. pneumoniae  1012; 4) = a susceptible reference 330 
strain E. coli ATCC 25922. (II), 5) = IMP-1-producing Klebsiella ozaenae  403; 6) = OXA-48-331 
producing K. pneumoniae  4019; 7) = ACT-32-producing E. cloacae  2009; 8) = TEM-332 
214+SHV-12+ACT-32-E. aerogenes  3009. 333 
 334 
 335 
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 336 
Table 1  337 
Summary of carbapenemase-producing and non-carbapenemase-producing Enterobacteriaceae used in this study.  338 
Species 
Carbapenemase producers (n = 31) Non-carbapenemase producers (n = 56) 
Ambler class A Ambler class B  MBL Ambler class D Ambler class A Ambler class C ESBL+AmpC 
KPC NDM VIM IMP OXA-48 like ESBL AmpC  
E. coli 2 1 - - 4 7 10 1 
K. pneumoniae 6 3 4* - 5 8 3 - 
E. aerogenes - - - - - - 7 5 
E. cloacae - 2 - - 2 - 8 1 
M. morganii - - - - - - 2 - 
C. freundii - - - - - - 2 2 
K. oxytoca 1 - - - - - - - 
K. ozaenae - - - 1 - - - - 
Total 9  11  11 15 32 9 
 339 
* One VIM-1 + SHV-12 and one VIM-1 + SHV-102 co-expresssions 340 
 341 
 342 
